ObjectiveTo explore the clinical effects of different doses of celecoxib combined with vitamin B6 in patients with apatinib-induced hand-foot syndrome (HFS) and their effect on the end diastolic velocity (EDV) and peak systolic velocity (PSV) of toe vessels. MethodsSixty patients with HFS due to apatinib treated in our hospital from April 2017 to March 2019 were selected, and they were randomly divided into group A (20 cases), group B (20 cases), and group C (20 cases). Patients in group A were administered low-dose (200 mg/d) celecoxib combined with vitamin B6, whereas group B with high-dose (400 mg/d) celecoxib combined with vitamin B6, and group C with vitamin B6, for three-week treatment courses. The clinical efficacy of the three groups was compared; the pre- and post-treatment levels of EDV and PSV in the three groups were detected and compared. ResultsAfter 3 weeks of treatment, the total effective rate of HFS was significantly higher in A and B groups than in group C, with statistically significant difference (P＜0.05); but there was no statistically significant difference between group A and group B (P＞0.05). Before treatment, there were no statistically significant differences in EDV and PSV levels between the three groups (P＞0.05). After 3 weeks of treatment, the EDV and PSV levels of the three groups increased significantly, and were higher in groups A and B than in group C, with statistically significant differences (P＜0.05); but there was no statistically significant difference between group A and group B (P＞0.05). ConclusionLow-dose or high-dose celecoxib combined with vitamin B6 is equivalent to the treatment of patients with HFS, and both of them can achieve a good clinical efficacy, and significantly improve the blood flow condition of toe vessels in patients.

无